Kymera Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good morning, everyone. Thanks for joining us for another session at the 44th JPMorgan healthcare conference. I'm Brian Cheng, one of the senior biotech analysts here at the firm. On stage, we have the CEO from Kymera Therapeutics, Nello Mainolfi. I'll now pass the mic to their CEO for a short presentation, followed by a live audience Q&A.
Nello, the stage is yours.
Thanks, Brian. Thanks, everybody, for joining us. Hopefully, the sound is good. Always great to be at JPMorgan in a new room this year. So in the next 20 to 30 minutes, I want to take the opportunity to tell you a little bit about Kymera, where we're going in 2026 and probably more importantly, where we're going in the next three to five years.
So if you look back -- so actually, this year, in May will be the tenth year anniversary since we founded Kymera and we spent the past 10 years building strategy capabilities and team to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
